A U Neumann

Summary

Affiliation: Bar-Ilan University
Country: Israel

Publications

  1. ncbi request reprint International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C
    Stefan Zeuzem
    Saarland University Hospital, Homburg Saar, Germany
    J Hepatol 43:250-7. 2005
  2. pmc Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study
    Geert Bezemer
    Dpt, Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands
    BMC Gastroenterol 12:11. 2012
  3. ncbi request reprint Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus
    A U Neumann
    Faculty of Life Sciences, Bar Ilan University, Ramat Gan 52900, Israel
    J Infect Dis 182:28-35. 2000
  4. ncbi request reprint Hepatitis B viral kinetics: a dynamic puzzle still to be resolved
    Avidan U Neumann
    Faculty of Life Sciences, University of Bar Ilan, Ramat Gan 52900, Israel
    Hepatology 42:249-54. 2005
  5. doi request reprint Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C
    Avidan U Neumann
    Goodman Faculty of Life Sciences, Bar Ilan University, Ramat Gan, Israel
    Liver Int 29:1350-5. 2009
  6. doi request reprint Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C
    Avidan U Neumann
    Bar Ilan University, Goodman Faculty of Life Sciences, Bldg 212, Rm 210, 52900 Ramat Gan, Israel
    J Hepatol 51:21-8. 2009
  7. doi request reprint The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin
    H Guedj
    Faculty of Life Sciences, Bar Ilan University, Ramat Gan, Israel
    J Viral Hepat 19:488-96. 2012
  8. doi request reprint Prediction of nonSVR to therapy with pegylated interferon-alpha2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment
    E Lukasiewicz
    The Mina and Everard Goodman Faculty of Life Sciences, Bar Ilan University, Ramat Gan, Israel
    J Viral Hepat 17:345-51. 2010
  9. doi request reprint Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics
    J Guedj
    The Everard and Mina Goodman Faculty of Life Sciences, Bar Ilan University, Ramat Gan 52900, Israel
    J Theor Biol 267:330-40. 2010
  10. ncbi request reprint Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production
    Harel Dahari
    Faculty of Life Science, Bar Ilan University, Ramat Gan 52900, Israel
    Gastroenterology 128:1056-66. 2005

Collaborators

Detail Information

Publications35

  1. ncbi request reprint International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C
    Stefan Zeuzem
    Saarland University Hospital, Homburg Saar, Germany
    J Hepatol 43:250-7. 2005
    ..The aim of this study was to increase virologic response rates by individualized treatment according to the early virologic response...
  2. pmc Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study
    Geert Bezemer
    Dpt, Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands
    BMC Gastroenterol 12:11. 2012
    ..HRQL improves after successful treatment. This trial explores the course of and factors associated with HRQL in patients given individualized or standard treatment based on early treatment response (Ditto-study)...
  3. ncbi request reprint Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus
    A U Neumann
    Faculty of Life Sciences, Bar Ilan University, Ramat Gan 52900, Israel
    J Infect Dis 182:28-35. 2000
    ..This is the first finding of a difference in viral dynamics between subtypes of the same virus and demonstrates the importance of subtype-specific virus-host-drug interactions...
  4. ncbi request reprint Hepatitis B viral kinetics: a dynamic puzzle still to be resolved
    Avidan U Neumann
    Faculty of Life Sciences, University of Bar Ilan, Ramat Gan 52900, Israel
    Hepatology 42:249-54. 2005
  5. doi request reprint Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C
    Avidan U Neumann
    Goodman Faculty of Life Sciences, Bar Ilan University, Ramat Gan, Israel
    Liver Int 29:1350-5. 2009
    ..In a phase 2 study of albIFN 1500 mug q2wk or q4wk in patients with genotype 2/3 chronic hepatitis C, albIFN demonstrated sustained virological response (SVR) rates of 62-77% (intent-to-treat population)...
  6. doi request reprint Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C
    Avidan U Neumann
    Bar Ilan University, Goodman Faculty of Life Sciences, Bldg 212, Rm 210, 52900 Ramat Gan, Israel
    J Hepatol 51:21-8. 2009
    ..The predictive value of early virologic response during albinterferon alfa-2b or peginterferon alfa-2a treatment was investigated in interferon-naïve patients with genotype 1, chronic hepatitis C...
  7. doi request reprint The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin
    H Guedj
    Faculty of Life Sciences, Bar Ilan University, Ramat Gan, Israel
    J Viral Hepat 19:488-96. 2012
    ..Further studies will be necessary to identify the biological mechanisms underlain by these findings...
  8. doi request reprint Prediction of nonSVR to therapy with pegylated interferon-alpha2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment
    E Lukasiewicz
    The Mina and Everard Goodman Faculty of Life Sciences, Bar Ilan University, Ramat Gan, Israel
    J Viral Hepat 17:345-51. 2010
    ..796). These results indicate that lack of sustained viral response is best predicted after 8 weeks of treatment and that waiting until 12 weeks does not improve the prediction...
  9. doi request reprint Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics
    J Guedj
    The Everard and Mina Goodman Faculty of Life Sciences, Bar Ilan University, Ramat Gan 52900, Israel
    J Theor Biol 267:330-40. 2010
    ..Thus, the ICCI model can explain the transient viral rebounds observed with DAA treatment as well as the viral resistance found in most patients with viral relapse at the end of DAA combination therapy...
  10. ncbi request reprint Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production
    Harel Dahari
    Faculty of Life Science, Bar Ilan University, Ramat Gan 52900, Israel
    Gastroenterology 128:1056-66. 2005
    ..Although hepatitis C virus kinetics and immune determinants during primary infection have been described, the virus-host interplay is not fully understood. We used mathematical modeling to elucidate and quantify virus-host dynamics...
  11. doi request reprint The role of positive feedback loops involving anti-dsDNA and anti-anti-dsDNA antibodies in autoimmune glomerulonephritis
    A Arazi
    Faculty of Life Sciences, Bar Ilan University, Ramat Gan, Israel Institute for Theoretical Biology, Humboldt University, Berlin, Germany
    J Theor Biol 319:8-22. 2013
    ..Several predictions can be derived from the analysis of the presented model, allowing its experimental verification...
  12. doi request reprint Modeling immune complex-mediated autoimmune inflammation
    A Arazi
    Faculty of Life Sciences, Bar Ilan University, Ramat Gan 52900, Israel
    J Theor Biol 267:426-36. 2010
    ..Our results can serve to guide the development of novel therapies to autoimmune diseases involving this type of inflammation...
  13. ncbi request reprint Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation
    Harel Dahari
    Faculty of Life Sciences, Bar Ilan University, 52900 Ramat Gan, Israel
    J Hepatol 42:491-8. 2005
    ..5-2h) to allow such analysis. Here we mathematically analyze viral decline during liver transplantation beyond the period of the anhepatic phase and examine the possibility of viral compartmentalization...
  14. pmc Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells
    Avidan U Neumann
    Goodman Faculty of Life Sciences, Bar Ilan University, Ramat Gan, Israel
    Hepatology 52:875-85. 2010
    ..This may have implications in designing new therapies for patients with chronic HBV infection and may also be relevant in other viral infections...
  15. pmc In vivo dynamical interactions between CD4 Tregs, CD8 Tregs and CD4+ CD25- cells in mice
    Arnon Arazi
    Faculty of Life Sciences, Bar Ilan University, Ramat Gan, Israel
    PLoS ONE 4:e8447. 2009
    ..Several subsets of Tregs have been identified to date; however, the dynamics of the interactions between these subsets, and their implications on their regulatory functions are yet to be elucidated...
  16. doi request reprint Mathematical modeling of viral kinetics under immune control during primary HIV-1 infection
    David Burg
    The Mina and Everard Goodman Faculty of Life Sciences, Bar Ilan University, Ramat Gan, Israel
    J Theor Biol 259:751-9. 2009
    ....
  17. ncbi request reprint Response to lamivudine treatment in children with chronic hepatitis B virus infection
    Stefan Hagmann
    Division of Pediatric Infectious Diseases, New York University School of Medicine, New York, New York 10016, USA
    Clin Infect Dis 37:1434-40. 2003
    ..Additional studies are necessary to provide better indications and guidelines for the treatment of children with chronic HBV infection...
  18. doi request reprint Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-alpha2a/ribavirin therapy
    Paolo Pugnale
    Department of Pathology and Immunology, University of Geneva Medical Center, 1211 Geneva, Switzerland
    J Hepatol 48:932-8. 2008
    ..Analysis of hepatitis C virus (HCV) RNA kinetics in compartments other than plasma may help in understanding HCV replication and identifying clinically significant patterns of treatment response...
  19. pmc Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity
    Helen Cooksley
    Institute of Hepatology, University College London, 69 75 Chenies Mews, London WC1E 6HX, United Kingdom
    Antimicrob Agents Chemother 52:312-20. 2008
    ..In conclusion, T-cell reactivity to HBV increases in a proportion of ADV-treated patients and is associated with greater suppression of HBV replication and HBeAg loss...
  20. ncbi request reprint HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project)
    Massimo Pilli
    Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    Gastroenterology 133:1132-43. 2007
    ....
  21. ncbi request reprint Impact of disease severity on outcome of antiviral therapy in treatment-naïve patients with chronic hepatitis C
    Johan Westin
    Hepatology 45:1333-4; author reply 1334. 2007
  22. ncbi request reprint Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6
    Esther Lukasiewicz
    Hepatology 45:258-9. 2007
  23. ncbi request reprint Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection
    Ana I Romero
    Department of Virology, University of Goteborg, Goteborg, Sweden
    J Infect Dis 194:895-903. 2006
    ..We investigated associations between interferon (IFN)-gamma-inducible protein (IP)-10 and liver histological results, viral kinetic response, and treatment outcome in patients infected with hepatitis C virus (HCV) genotypes 1-4...
  24. ncbi request reprint Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication
    Magali Bouvier-Alias
    Department of Virology EA 3489, Hopital Henri Mondor, Universite Paris XII, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
    Hepatology 36:211-8. 2002
    ..Nevertheless, the total HCV core Ag assay cannot be used as a marker of viral replication for HCV RNA values below 20,000 IU/mL, limiting its use in the monitoring of late events during and after antiviral treatment...
  25. ncbi request reprint The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine
    Leonieke M M Wolters
    Department of Hepatogastroenterology, University Hospital Rotterdam, The Netherlands
    J Hepatol 37:253-8. 2002
    ..Viral decline during lamivudine therapy in chronic hepatitis B patients is bi-phasic. We studied the influence of lamivudine dose and baseline characteristics on parameters obtained from a mathematical model...
  26. ncbi request reprint Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees
    Marian E Major
    Laboratory of Hepatitis Viruses, Division of Viral Products Center for Biologics Evaluation and Research Food and Drug Administration, Bethesda, MD, USA
    Hepatology 39:1709-20. 2004
    ..However, the pathogenesis of HCV may be determined by a more rapid onset of the induced response and the cell population that migrates to the liver...
  27. ncbi request reprint Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C
    Thomas J Layden
    University of Illinois at Chicago, Chicago, IL
    J Viral Hepat 9:334-9. 2002
    ..They also suggest that early viral kinetics during the first month of therapy can predict non-SVR and thus save a patient a year long treatment which is fraught with side-effects and significant cost...
  28. ncbi request reprint A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy
    Vijayan Balan
    Mayo Clinic, Phoenix, AZ, USA
    Antivir Ther 11:35-45. 2006
    ..These results support further clinical studies of albumin-IFN-alpha for the treatment of patients with chronic hepatitis C...
  29. ncbi request reprint First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline
    Jennifer E Layden
    University of Illinois at Chicago, Chicago, IL, USA
    J Viral Hepat 9:340-5. 2002
    ..This might be explained by a viral dynamics model assuming a jump-start of the immune response when viral loads are reduced below a threshold, subsequently giving rise to a faster 2nd phase decline slope...
  30. ncbi request reprint IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection
    Martin Lagging
    Department of Infectious Diseases, University of Goteborg, Sweden
    Hepatology 44:1617-25. 2006
    ..Thus, pretreatment IP-10 analysis may prove helpful in decision-making regarding pharmaceutical intervention...
  31. ncbi request reprint Virus dynamics and immune responses during treatment in patients coinfected with hepatitis C and HIV
    Andrew H Talal
    Department of Medicine, Weill Medical College of Cornell University, New York City, NY, USA
    J Acquir Immune Defic Syndr 35:103-13. 2004
    ....
  32. ncbi request reprint A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection
    Johan Westin
    Department of Infectious Diseases, Goteborg University, Sweden
    Scand J Gastroenterol 43:73-80. 2008
    ....
  33. doi request reprint Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation
    Michael Y Shapira
    Hadassah Hebrew University Medical Center, Jerusalem, Israel
    Clin Infect Dis 46:1455-7. 2008
    ..Artesunate treatment resulted in a 1.7-2.1-log reduction in viral load by treatment day 7, with a viral half-life of 0.9-1.9 days, indicating a highly effective block in viral replication...
  34. ncbi request reprint Immunodeficiency and intrinsic IFN resistance are associated with viral breakthrough to HCV therapy in HIV-coinfected patients
    Veronique Nussenblatt
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892, USA
    AIDS Res Hum Retroviruses 23:1354-9. 2007
    ..HIV/HCV-coinfected patients have a high rate of VB on PEG-IFN/RBV therapy characterized by higher levels of IFIG expression, immunodeficiency, and hepatic inflammation. Novel strategies are required for the treatment of persons with VB...
  35. ncbi request reprint Antiviral action of ribavirin in chronic hepatitis C
    Jean Michel Pawlotsky
    Department of Virology, INSERM U635, Hopital Henri Mondor, Universite Paris XII, Creteil, France
    Gastroenterology 126:703-14. 2004
    ..Our aim was to assess the antiviral action of ribavirin on hepatitis C virus (HCV) as a function of ribavirin pharmacokinetics and to evaluate the influence of this antiviral effect on IFN-alpha efficacy...